Non-myeloablative allogeneic stem cell transplant with fludarabine and reduced dose cyclophosphamide in acute myeloid leukemia for older adults with comorbidities

Bone Marrow Transplant. 2022 Nov;57(11):1743-1745. doi: 10.1038/s41409-022-01821-4. Epub 2022 Sep 12.

Authors

Affiliations

¹ Penn State Cancer Institute, 500 University Dr, Hershey, PA, 17033, USA.
² Division of Biostatistics and Bioinformatics, Penn State College of Medicine, 700 HMC Crescent Road, Hershey, PA, 17033, USA.
³ Penn State Cancer Institute, 500 University Dr, Hershey, PA, 17033, USA. kminagawa@pennstatehealth.psu.edu.

PMID: 36097041
DOI: 10.1038/s41409-022-01821-4

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Busulfan
Cyclophosphamide
Graft vs Host Disease*
Hematopoietic Stem Cell Transplantation*
Humans
Leukemia, Myeloid, Acute* / therapy
Retrospective Studies
Transplantation Conditioning
Vidarabine

Substances

fludarabine
Vidarabine
Cyclophosphamide
Busulfan